Galenok V A, Zhuk E A
Ter Arkh. 1995;67(10):7-12.
The authors review literature data and their own experience on immunopathogenesis of diabetes mellitus types I and II, discuss desirability of immunomodulating drugs inclusion in the treatment schemes, application of immune system mediators and synthetic immunomodulators, selection of patients for immunocorrection. Immunomodulating therapy in diabetes mellitus is thought beneficial though further serious studies are required.
